A new guideline is coming! The AGA Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in Immunosuppressed Individuals will be published in February 2025.
Hepatitis B reactivation (HBVr) can occur in patients experiencing chronic immunosuppression. The goal of this guideline is to inform and guide frontline health practitioners on how to prevent and manage HBVr in their practice.
As part of our guideline development process, we invite you to review this draft guideline and share feedback during the public comment period.
Submit your comments by Sept. 25, 2024.
Guideline documents for review
About the public comment period
AGA develops clinical practice guidelines using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which provides a common, sensible and transparent approach to grading the quality of evidence and strength of recommendations, and uses the best practices outlined by the Institute of Medicine.
The public comment period is an integral part of AGA’s guideline development process. It allows AGA members and key stakeholders to review and comment on upcoming guidelines and their accompanying technical reviews.
Once an AGA guideline panel releases the drafts for public comment, identified stakeholders are alerted and submit their comments through an online survey. After the period ends, the guideline panel reviews and responds to the comments within two weeks. Revisions to the draft documents are at the discretion of the panel, but all comments will be considered and responses internally documented.
To see previously published guidelines, visit AGA’s clinical guidance library.
